Cutaneous Lupus Erythematosus

A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).

Also Known As:

Networked: 833 relevant articles (56 outcomes, 52 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Systemic Lupus Erythematosus (Libman-Sacks Disease)
2.	Skin Diseases (Skin Disease)
3.	Solar Urticaria
4.	Psoriasis (Pustulosis Palmaris et Plantaris)
5.	Dermatomyositis (Dermatopolymyositis)

Experts

1.	Werth, Victoria P: 30 articles (10/2022 - 09/2002)
2.	Wenzel, Joerg: 19 articles (01/2022 - 03/2005)
3.	Kuhn, Annegret: 14 articles (01/2021 - 04/2002)
4.	Bieber, Thomas: 13 articles (01/2021 - 03/2005)
5.	Callen, Jeffrey P: 12 articles (04/2021 - 04/2002)
6.	Francès, Camille: 11 articles (01/2022 - 04/2012)
7.	Chasset, François: 10 articles (01/2022 - 04/2015)
8.	Kreuter, Alexander: 8 articles (04/2022 - 09/2004)
9.	Bieber, T: 8 articles (11/2011 - 07/2005)
10.	Tüting, T: 8 articles (11/2011 - 07/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cutaneous Lupus Erythematosus:

1.	Antimalarials (Antimalarial Agents)IBA 08/01/2020 - "No significant differences were observed in the Cutaneous Lupus Erythematosus Disease Area and Severity Index activity when the efficacy of antimalarials was analyzed between smokers and non-smokers. " 04/01/2015 - "Interaction between smoking and efficacy of antimalarials, the mainstay of treatment for cutaneous lupus erythematosus (CLE), remains controversial. " 06/01/2012 - "Smoking seems to inhibit the therapeutic efficacy of antimalarials when treating cutaneous lupus erythematosus (CLE), but the reason behind this observation is unclear. " 01/01/1998 - "There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. " 08/01/2015 - "Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus."
2.	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 03/01/2020 - "Hydroxychloroquine is widely used for the treatment of cutaneous lupus erythematosus (CLE). " 08/01/2018 - "Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients." 04/01/2019 - "However, the efficacy of hydroxychloroquine in various cutaneous lupus erythematosus subtypes in Japanese patients has not been elucidated to date. " 01/01/2017 - "Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial." 04/01/2012 - "To study the relation between blood concentration of hydroxychloroquine and the clinical efficacy of hydroxychloroquine sulfate in a series of patients with cutaneous lupus erythematosus (CLE). "
3.	Tacrolimus (Prograf)FDA LinkGeneric 04/01/2005 - "[Topical treatment of subacute-cutaneous lupus erythematosus with tacrolimus]." 04/01/2003 - "Topical tacrolimus for cutaneous lupus erythematosus." 01/01/2003 - "Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. " 01/01/2002 - "Topical tacrolimus therapy was applied to facial skin lesions in 11 cases of cutaneous lupus erythematosus (LE) and dermatomyositis. " 01/01/2002 - "Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis."
4.	Thalidomide (Thalomid)FDA Link 12/07/2021 - "Thalidomide is effective in patients with refractory cutaneous lupus erythematosus (CLE). " 03/01/2012 - "Although thalidomide has been shown to be effective in patients with refractory cutaneous lupus erythematosus (CLE), its use is still hampered by its potential severe side-effects and the current restricted availability. " 11/01/2008 - "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment. " 09/01/2021 - "Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). " 07/01/2018 - "Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study."
5.	DapsoneFDA Link 01/01/2019 - "Dapsone: an old drug effective for subacute cutaneous lupus erythematosus." 01/01/2001 - "The affected gland was excised and the cutaneous lupus erythematosus was improved considerably by oral Dapsone." 01/01/2016 - "A variety of therapeutic options have been reported for cutaneous lupus erythematosus (CLE); one of these is dapsone. " 01/01/2016 - "Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? " 04/01/1996 - "Dapsone syndrome in cutaneous lupus erythematosus."
6.	Mycophenolic Acid (Cellcept)FDA LinkGeneric 06/01/2007 - "This was a prospective, nonrandomized, open pilot study to evaluate the efficacy of mycophenolate sodium monotherapy in patients with recalcitrant subacute cutaneous lupus erythematosus (SCLE). " 11/01/2013 - "Few studies have evaluated the effects and precise molecular mechanism of mycophenolate mofetil (MMF) in the treatment of human cutaneous lupus erythematosus (CLE). " 08/01/2019 - "Treatment of exfoliative cutaneous lupus erythematosus in a German shorthaired pointer dog with mycophenolate mofetil." 01/01/2016 - "Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence." 11/01/2013 - "Effects of mycophenolate mofetil on cutaneous lupus erythematosus in (NZB × NZW) F1 mice."
7.	Isotretinoin (Accutane)FDA LinkGeneric 05/01/2012 - "Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option." 10/01/1990 - "Subacute cutaneous lupus erythematosus response to isotretinoin." 06/01/1989 - "In the light of these results, isotretinoin can be considered as an effective and well-tolerated drug in the treatment of cutaneous lupus erythematosus." 06/01/1989 - "[Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus]." 02/01/1986 - "Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus."
8.	Ointments (Pastes)IBA 07/01/2011 - "Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial." 01/01/2004 - "0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus." 01/01/2010 - "Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study." 07/01/2012 - "A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index."
9.	belimumabIBA 01/01/2023 - "Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta-Analysis." 03/01/2020 - "[Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study]." 10/01/2021 - "Belimumab in subacute cutaneous lupus erythematosus." 05/01/2021 - "Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab." 03/01/2020 - "The aim of our study was to evaluate the efficacy of belimumab in the treatment of cutaneous lupus erythematosus (CLE), resistant to conventional therapy. "
10.	AcitretinFDA Link 06/01/1988 - "It is concluded that acitretin is a highly effective and well-tolerated drug in the treatment of cutaneous lupus erythematosus." 06/01/1988 - "Efficiency of acitretin in the treatment of cutaneous lupus erythematosus." 11/01/1992 - "A randomized, double-blind, multicentre study was performed to compare the efficacy of acitretin (50 mg/day) with hydroxychloroquine (400 mg/day) in 28 and 30 patients, respectively, suffering from cutaneous lupus erythematosus (LE). " 11/01/1992 - "Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine."

Therapies and Procedures

1.	Therapeutics 08/01/2019 - "Immune-modulating drugs show limited therapeutic efficacy in canine exfoliative cutaneous lupus erythematosus (ECLE); over half of ECLE dogs are eventually euthanized for their lack of response to therapy. " 01/01/2006 - "Large, controlled trials are needed, not only to evaluate newer therapies, but also to substantiate and define the usage of traditional therapies for cutaneous lupus erythematosus." 05/01/2023 - "Food and Drug Administration (FDA) approved therapies for cutaneous lupus erythematosus (CLE). " 09/14/2022 - "Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus." 01/01/2022 - "Emerging Therapies in Cutaneous Lupus Erythematosus."
2.	Aftercare (After-Treatment) 01/01/2013 - "Subacute cutaneous lupus erythematosus after treatment with capecitabine." 07/10/2011 - "Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil." 01/01/2020 - "Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals." 08/01/2004 - "We describe the results of minimal erythema dose (MED) testing in nonlesional skin of three patients with chronic cutaneous lupus erythematosus (CCLE) before and after treatment with thalidomide. " 08/01/2008 - "Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine."
3.	Immunomodulation 11/01/2016 - "Immunomodulation in cutaneous lupus erythematosus subsets." 01/01/1987 - "Due to its influence on dermal inflammatory processes and immunomodulation of the tissue response, etretinate is effective in cutaneous lupus erythematosus, certain bullous disorders like pemphigus herpetiformis, the persistent variant of Grover's disease, dermatitis herpetiformis, and bullous pemphigoid. "
4.	Plasmapheresis 06/01/2008 - "Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus." 01/01/2013 - "A case of subacute cutaneous lupus erythematosus in a patient with mixed connective tissue disease: successful treatment with plasmapheresis and rituximab."
5.	Drug Tapering 01/01/2022 - "Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients." 06/01/2022 - "Key secondary outcomes were the difference between the anifrolumab 300 mg group and the placebo group in: proportion of patients in the interferon gene signature test-high subgroup who achieved SRI-4 at week 52; proportion of patients on 10 mg/day or more corticosteroids at baseline who achieved a sustained dose reduction to 7·5 mg/day or less from week 40 to 52; proportion of patients with a cutaneous lupus erythematosus disease area and severity index (CLASI) activity score of 10 or higher at baseline who achieved a 50% or more reduction in CLASI score by week 12; proportion of patients who achieved SRI-4 at week 24; and annualised flare rate through week 52. "